Thomas Michler

1.3k citations

26 papers · 666 indexed · h-index 14

Impact in

Hepatology top 5%
- Hepatitis C virus research
Infectious Diseases top 10%
- SARS-CoV-2 and COVID-19 Research

Papers in

Hepatology 9
- Hepatitis C virus research 9
- Hepatitis Viruses Studies and Epidemiology 3
Infectious Diseases 11
- Viral gastroenteritis research and epidemiology 4
- SARS-CoV-2 and COVID-19 Research 3

Co-authors: Ulrike Protzer Stoyan Velkov Jördis J. Ott Olivia M. Merkel Aditi Mehta Julie Lucifora Chunkyu Ko Karin Wisskirchen
Journals: Journal of Hepatology (3 papers)Gastroenterology (2 papers)Scientific Reports (1 paper)Molecular & Cellular Proteomics (1 paper)EMBO Molecular Medicine (1 paper)
Partner nations: Germany France United States

In The Last Decade

Thomas Michler

26 papers receiving 660 citations

Peers

Countries citing papers authored by Thomas Michler

Since Specialization

Citations

This map shows the geographic impact of Thomas Michler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Michler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Michler more than expected).

Fields of papers citing papers by Thomas Michler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Michler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Michler. The network helps show where Thomas Michler may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Thomas Michler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas Michler Line = papers co-authored together Thomas Michler links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The lack of HBsAg secretion does neither facilitate induction of antiviral T cell responses nor Hepatitis B Virus clearance in mice Antiviral Research ·Thomas Michler, Rennie Martinez, Tsigewoin Tekleab, Нина Михайловна Егорова, Julia Festag, Anna D. Kosinska, Ulrike Protzer	2024	2
2	Implementation and User Satisfaction of a Comprehensive Telemedicine Approach for SARS-CoV-2 Self-Sampling: Monocentric, Prospective, Interventional, Open-Label, Controlled, Two-Arm Feasibility Study JMIR Formative Research ·Florian Voit, Johanna Erber, Yasmiar Yasmiar, D.A. Iskra, Michael Laxy, Victoria Kehl, Dieter Hoffmann, Samuel Jeske, Thomas Michler, Ulrike Protzer, Florian Kohlmayer, Roland M. Schmid, Christoph D. Spinner, Avinash G. Vishakantegowda	2024	1
3	Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes Journal of Controlled Release ·Domizia Baldassi, سناء حسن عماشة, Martin Feuerherd, Cho‐Chin Cheng, David J. Peeler, Daniel P. Feldmann, Diana Porras-Gonzalez, Xin Wei, Maria Remén, Nikolaus Kneidinger, Mircea Gabriel Stoleriu, Andreas Popp, Gerald Burgstaller, Suzie H. Pun, Thomas Michler, Olivia M. Merkel	2022	36
4	Unravelling the role of hepatocytes in hepatitis B virus specific immunotolerance Zeitschrift für Gastroenterologie ·Ossamma Tawfik, سناء حسن عماشة, Ulrike Protzer, Thomas Michler	2022	1
5	PD-L1 Silencing in Liver Using siRNAs Enhances Efficacy of Therapeutic Vaccination for Chronic Hepatitis B Biomolecules ·Raisa Rauf, Anna D. Kosinska, Thomas Michler, Ulrike Protzer	2022	18
6	siRNA Therapeutics against Respiratory Viral Infections—What Have We Learned for Potential COVID‐19 Therapies? Advanced Healthcare Materials ·Aditi Mehta, Thomas Michler, Olivia M. Merkel	2021	57
7	Hypoxic gene expression in chronic hepatitis B virus infected patients is not observed in state-of-the-art in vitro and mouse infection models Scientific Reports ·Peter Liu, James Michael Harris, Emanuele Marchi, Valentina D’Arienzo, Thomas Michler, Peter A. C. Wing, Andrea Magrì, Ana Maria Ortega‐Prieto, Ken Cushner, Jochen M. Wettengel, David Durantel, Marcus Dorner, Paul Klenerman, Ulrike Protzer, Efstathios S. Giotis, Jane A. McKeating	2020	14
8	Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing Molecular & Cellular Proteomics ·Jana Zecha, Chien‐Yun Lee, Florian Bayer, Chen Meng, Vincent Grass, Johannes Zerweck, Karsten Schnatbaum, Thomas Michler, Andreas Pichlmair, Christina Ludwig, Bernhard Küster	2020	65
9	Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice Gastroenterology ·Thomas Michler, Anna D. Kosinska, Julia Festag, Raisa Rauf, Jinpeng Su, Marc Ringelhan, Kaida Lin, Dirk Grimm, Katja Steiger, Carolin Mogler, Mathias Heikenwälder, Marie-Louise Michel, Carlos A. Guzmán, Stuart Milstein, Laura Sepp‐Lorenzino, Percy A. Knolle, Ulrike Protzer	2020	92
10	Induction of Functional Control in Chronic Hepatitis B Patients with Low Level HBsAg Using a Combination of a PreS1/S2/S HBV Vaccine (Sci-BVacTM) and a Nucleoside Analogue Journal of Infectious Diseases and Therapy ·Hedwig Roggendorf, Adalbert Krawczyk, Monika Lindemann, Daniel Shouval, Thomas Michler, Michael Roggendorf, G Gerken	2019	3
11	One-Vector System for Multiplexed CRISPR/Cas9 against Hepatitis B Virus cccDNA Utilizing High-Capacity Adenoviral Vectors Molecular Therapy — Nucleic Acids ·Jingyi Zhao, Eric Ehrke‐Schulz, Andreas Oswald, Thorsten Bergmann, Thomas Michler, Ulrike Protzer, Anja Ehrhardt	2018	61
12	Combinatorial RNAi/vaccination therapy for chronic hepatitis B achieves long-term functional cure in preclinical mouse model Journal of Hepatology ·Thomas Michler, Anna D. Kosinska, Raisa Rauf, Mathias Heikenwälder, Daniela Grimm, Stuart Milstein, Laura Sepp‐Lorenzino, Ulrike Protzer	2018	3
13	Novel viral and host targets to cure hepatitis B Current Opinion in Virology ·Chunkyu Ko, Thomas Michler, Ulrike Protzer	2017	21
14	Preclinical study of a combinatorial RNAi/vaccination therapy as a potential cure for chronic hepatitis B Journal of Hepatology ·Thomas Michler, Anna D. Kosinska, Raisa Rauf, Mathias Heikenwälder, Daniela Grimm, Stuart Milstein, Laura Sepp‐Lorenzino, Ulrike Protzer	2017	2
15	Blocking sense‐strand activity improves potency, safety and specificity of anti‐hepatitis B virus short hairpin RNA EMBO Molecular Medicine ·Thomas Michler, Stefanie Große, H. P. D., N. Kodra, Ferdinand Stückler, Bettina L. Knapp, Chunkyu Ko, Mathias Heikenwälder, Ulrike Protzer, Dirk Grimm	2016	24
16	RNA Interference Mediated Suppression of HBV Transcripts Restores HBV-Specific Immunity and Enhances the Efficacy of Therapeutic Vaccination Journal of Hepatology ·Thomas Michler, Anna D. Kosinska, M. A. Ganesh, M Kaufmann, Daniela Grimm, Mathias Heikenwälder, Michael Roggendorf, Ulrike Protzer	2016	2
17	New pharmacological strategies to fight enveloped viruses Trends in Pharmacological Sciences ·Karin Wisskirchen, Julie Lucifora, Thomas Michler, Ulrike Protzer	2014	49
18	Hepatitis B virus infection enhances susceptibility toward adeno-associated viral vector transduction in vitro and in vivo Hepatology ·Marianna Hösel, Julie Lucifora, Thomas Michler, Ning Yong-gang, Marion Gruffaz, Stephanie Stahnke, Fabien Zoulim, David Durantel, Mathias Heikenwälder, Dirk Nierhoff, Eva Qviberg, Anna Salvetti, Ulrike Protzer, Hildegard Büning	2014	18
19	Correlation of fulminant hepatitis B, HBeAg start-codon depletions and escape mutations in the 2nd loop of the HBsAg a-determinant International Journal of Infectious Diseases ·Thomas Michler, V. Uma Maheshwari Nallal, F Kuemmerle, Christian Bach, Tanja Bauer, Ulrike Protzer	2014	1
20	Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms American Journal of Physiology-Gastrointestinal and Liver Physiology ·Thomas Michler, Martin Storr, Johannes Krämer, Ahmad Kamel Bin Mohamed, Antje Malo, Simone Reu, Burkhard Göke, Claus Schäfer	2012	33

About Thomas Michler

Thomas Michler is a scholar working on Hepatology, Infectious Diseases, Epidemiology, Virology and Endocrinology, having authored 26 papers that have together received 666 indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (15 papers), Hepatitis C virus research (9 papers), RNA Interference and Gene Delivery (7 papers), Liver Disease Diagnosis and Treatment (6 papers), Viral gastroenteritis research and epidemiology (4 papers), Virus-based gene therapy research (3 papers), SARS-CoV-2 and COVID-19 Research (3 papers) and Hepatitis Viruses Studies and Epidemiology (3 papers). The work is most often cited by research in Hepatology (227 citations), Infectious Diseases (202 citations), Epidemiology (339 citations), Immunology (105 citations) and Molecular Biology (260 citations). Thomas Michler has collaborated with scholars based in Germany, France and United States. Frequent co-authors include Ulrike Protzer, Stoyan Velkov, Jördis J. Ott, Olivia M. Merkel, Aditi Mehta, Julie Lucifora, Chunkyu Ko, Karin Wisskirchen, Anna D. Kosinska and Mathias Heikenwälder. Their work appears in journals such as Journal of Hepatology, Gastroenterology, Scientific Reports, Molecular & Cellular Proteomics and EMBO Molecular Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact